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Herpes Simplex Virus (HSV) infection is an incurable disease that afflicts as much as 50% of adults 
in the United States. This virus establishes a life-long infection in neuronal cells of the trigeminal 
ganglia and/or dorsal root ganglia. Periodic reactivation of the latent virus results in symptomatic 
cold sores on the mouth or genitals and viral shedding. Despite effectively reducing both the 
frequency and intensity of these episodes, antiviral medication does not eradicate the latent viral 
genomes from the infected cells. A novel curative approach involving rare-cleaving endonucleases 
to target viral DNA is being developed in the laboratory of Dr. Keith Jerome of the Vaccine and 
Infectious Disease Division. A recent study published in Molecular Therapy–Nucleic Acids shows 
promising results of this approach in an in vitro cell model for HSV latency. 
Homing endonucleases (HE) are a type of rare-cleaving endonuclease that recognize and cleave 
large DNA sequences (usually around 20 base pairs). Upon recognition of their target sequence, 
HEs induce a double strand break in the DNA, which is typically repaired by the host cell via a DNA 
repair mechanism called nonhomologous end joining. This error-prone repair process can cause 
DNA mutations that can inactivate the gene that harbors the target sequence. By developing a 
homing endonuclease to specifically target a sequence contained in the HSV genome, the Jerome 
Lab hopes to successfully inactivate latent HSV and thus offer the possibility of a cure.  
In their study, senior staff scientist Dr. Martine Aubert et al. first established an in vitro cell model for 
HSV latency. To create this model, primary human fibroblasts are infected with HSV and then 
treated with antiviral drugs to stop viral replication and establish latency. During latency, HSV 
persists in infected cells as a double-stranded circular DNA genome. The researchers can later 
induce HSV to come out of this latent state, a process called reactivation. With the HSV latency 
model in hand, they tested the effects of a HE that targets a sequence in the HSV UL19 gene, which 
is essential for viral replication. Upon treatment of the cells with the HE, site-specific mutations were 
detected in the target site within HSV, indicating successful cleavage and mutagenic repair of the 
target sequence. Additionally, a drop in HSV production and viral DNA replication were observed in 
the HE-treated cells upon reactivation. 
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After confirming antiviral activity following treatment with HE, Aubert et al. examined additional 
methods to improve upon this therapeutic strategy. First, increased mutagenic activity was observed 
when HE was co-delivered with Trex2, a 3’ exonuclease that increases the rate of mutagenic repair 
of double strand breaks. Second, delivery of the HE and Trex2 was accomplished via the use of an 
adeno-associated virus (AAV) vector. The efficient delivery of a transgene expressing a therapeutic 
enzyme is of fundamental importance when translating such an approach into animal testing and 
eventually the clinic. Third, accessibility of HSV DNA is affected by slight variations in the DNA that 
dictate its chromatin structure, or the extent to which the DNA forms tightly wound up coils. Through 
the use of histone deacetylase inhibitors, which function to relax tightly coiled DNA and allow better 
access to the sequence, the researchers increased the rate of HE-induced targeted mutations. This 
was accomplished by providing the HE with better access to the target sequence in the DNA. 
These promising results highlight the initial advances being made in the field of targeted gene 
disruption. The Jerome Lab is also experimenting with utilizing this strategy to target other latent and 
persistent viral infections such as hepatitis B virus and human immunodeficiency virus (HIV). "While 
we've seen great excitement recently about the possibility of a cure for HIV, relatively little attention 
has been paid to cures for other latent viral infections like HSV," explains Dr. Jerome. "These 
findings show that attacking the latent virus where it hides in cells is possible." Indeed, the ability to 
specifically identify pathogenic viral DNA and inactivate it through DNA cleavage is a powerful 
notion. "We're excited to continue to develop this approach toward clinical application," says Dr. 
Jerome. 
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Image provided by Dr. Martine Aubert. 
Latent HSV infection persists in neuronal cell bodies from where it can reactivate and cause lesions 
and viral shedding in the peripheral epithelium. By targeting the latent episomal HSV genome with 
an endonuclease, viral replication can be inhibited stopping reactivation and thus eliminating 
symptoms and transmission to new hosts, resulting in the possibility of a cure. 
 
